Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research

Tetraphase receives BARDA contract to develop new antibiotic

PBR Staff Writer Published 17 February 2012

Tetraphase Pharmaceuticals has received $67m contract from Biomedical Advanced Research and Development Authority (BARDA) for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens.

The BARDA contract includes pre-clinical efficacy and toxicology studies; clinical studies; manufacturing activities; and associated regulatory activities of TP-434.

The contract includes a 12-month base period with committed funding of $11.5m and subsequent option periods that, if completed, would bring the total value of the award to approximately $67m.

Tetraphase will work on this contract with CUBRC, the company said.

TP-434 as a potential empiric countermeasure for the treatment of inhalational disease caused by Bacillus anthracis, Francisella tularensis and Yersinia pestis.

Tetraphase president and CEO Guy Macdonald said BARDA's award covering the development of TP-434 brings the total federal funding in support of the development of Tetraphase's antibiotics to more than $100m.


Post a comment

Comments may be moderated for spam, obscenities or defamation.